国产99热精品_欧美疯狂做受xxxx猛交_婷婷在线网站_日韩无遮挡毛片_欧美高清momspuss_欧美激情福利

復(fù)旦張江
上海復(fù)旦張江生物醫(yī)藥股份有限公司，一九九六年十一月創(chuàng)建于上海浦東張江高科技園區(qū)之“張江藥谷”，上海醫(yī)藥集團(tuán)股份有限公司、中國(guó)通用技術(shù)（集團(tuán)）控股有限責(zé)任公司、張江高科技園區(qū)開(kāi)發(fā)股份有限公司和復(fù)旦資產(chǎn)經(jīng)營(yíng)有限公司等知名企業(yè)和大學(xué)為公司主要股東。

本著"我們多一分探索，人類多一分健康"的信念，公司主要從事生物醫(yī)藥的創(chuàng)新研究、開(kāi)發(fā)、生產(chǎn)和銷售，力求成為一家以知識(shí)產(chǎn)權(quán)為核心源泉的生物醫(yī)藥創(chuàng)新企業(yè)。經(jīng)過(guò)多年的不懈努力，公司在基因工程藥物、光動(dòng)力藥物、醫(yī)學(xué)診斷及藥物傳輸系統(tǒng)等領(lǐng)域不斷推出新產(chǎn)品，形成了明顯的競(jìng)爭(zhēng)優(yōu)勢(shì)，預(yù)計(jì)未來(lái)每年將有一二個(gè)新藥投放市場(chǎng)。

憑籍在生物醫(yī)藥領(lǐng)域的實(shí)力，公司多次擔(dān)綱國(guó)家級(jí)研發(fā)項(xiàng)目，包括國(guó)家重點(diǎn)科技項(xiàng)目計(jì)劃和國(guó)家高技術(shù)研究發(fā)展計(jì)劃（八六三計(jì)劃）等。一九九八年以來(lái)，公司被連續(xù)認(rèn)定為“高新技術(shù)企業(yè)”，一九九九年，公司被國(guó)家人事部批準(zhǔn)為“企業(yè)博士后科研工作站”。二〇〇二年八月，公司在香港創(chuàng)業(yè)板成功上市（股票代碼：8231）。

公司現(xiàn)控股上海摩根談國(guó)際生命科學(xué)中心有限公司、上海靶點(diǎn)藥物有限公司及泰州復(fù)旦張江藥業(yè)有限公司，參股上海先導(dǎo)藥業(yè)有限公司。公司人力資源豐富，技術(shù)力量強(qiáng)大，近200名高素質(zhì)的員工將推動(dòng)公司不斷創(chuàng)新，實(shí)現(xiàn)飛躍。

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (FDZJ) was established in Novmber,1996 and located in the “Drug Valley”, Zhangjiang Hi-tech Park, Pudong District, Shanghai. The shareholders include Shanghai Pharmaceuticals Holding Co.,Ltd., Genertech Holding Co., Ltd., Zhangjiang Hi-tech Development Co., Ltd., Fudan University.

With the philosophy of “the more we probe, the healthier the people will be”, aiming at becoming an innovative bio-medical company possessing intellectual properties as the core competitive force, the company deals with new drug R&D as well as production and sales. Many years of the persistent effort have brought many new results in the R&D of genetic engineering drugs, photodynamic drugs, diagnosis reagents and new dosage forms with the improving drug delivery properties and competitive advantage for the company. One or two new drugs will be launched every year since this year.

Owing to the strength of the R&D in bio-pharmaceutical field, the company has played an important role in many national R&D projects, such as national key project of science and technology development and national hi-tech R&D projects. The company has continuously characterized as an Advance Science and Technology Enterprise since 1998, recognized as a Postdoctoral Study Station since 1999 and fulfilled the procedure of IPO listed in Hong Kong GEM since 2002.

The company organized four subsidiary companies: Shanghai Morgan Tan International Centre for Life Science, Taizhou Fudan-Zhangjiang Pharmaceutical Co.,Ltd., Shanghai TargetDrug Pharmaceutical Co.,Ltd. And Shanghai Lead Discovery Pharmaceutical Co., Ltd. Due to the rich brain-source and strong technical source, about 200 staff member well educated and trained will surely create more and push the company go forward rapidly.